US 10,000,558 B2Granted

Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma

AssigneeVersitech Limited

InventorsStephanie Kwai Yee Ma, Man Tong, Xin-Yuan Guan

Life of this patent

Estimating the term…

Abstract

Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.

Claims9

Dependent claims

An antibody that specifically binds to a portion of human ANXA3 protein, the portion consisting of SEQ ID NO:

Dependencies are inferred from the claim text.

Facts

Application: 15/238,328Filed 16 Aug 2016 · continuation in part
Priority: 12 Sep 2013
Published: US 2017/0037116 A19 Feb 2017
Granted: 19 Jun 2018
Term ends: Not estimatedThe source records don’t support an estimate.

Classification25 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61P 35/00
Antineoplastic agents
C07K 16/303
From tumour cells: liver or Pancreas
C12N 15/1137
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against enzymes

Family

Application61/877,061Us provisional application · filed 12 Sep 2013
Application14/485,206Parent of this continuation-in-part · filed 12 Sep 2014
US 2017/0037116 A1Pre-grant publication · published 9 Feb 2017
US 9,487,831 B2Parent of this continuation-in-part
US 2015/0071933 A1Published application
US 10,000,558 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results